Navigation Links
Clinical Genomics Pty Ltd and The Garvan Institute of Medical Research Enter into Licensing Agreement
Date:9/27/2010

SYDNEY, Sept. 27 /PRNewswire/ -- Clinical Genomics Pty. Ltd (Sydney, Australia) and The Garvan Institute of Medical Research (Sydney, Australia) today announced that they have entered into a license agreement in relation to novel biomarkers discovered by scientists at the Garvan Institute. Under the terms of the agreement, Clinical Genomics obtains worldwide exclusive rights to the Garvan's proprietary cancer associated methylation DNA biomarkers for the diagnosis and or treatment of colorectal cancer. Clinical Genomics intends to expand its colorectal biomarker research program to evaluate these promising biomarkers in view of formulating a diagnostic test utilizing those biomarkers demonstrating clinical benefit for the early detection of colorectal cancer.

"Through this strategic licensing agreement with the Garvan Institute, we have complemented our existing technology portfolio and enhanced our ability to develop next generation products for diagnosing colorectal cancer at the earliest, most treatable stage," stated Dr. Lawrence LaPointe, Chief Executive Officer of Clinical Genomics. "We have also broadened our product development options for ourselves and our partners."

"This licensing agreement will allow Clinical Genomics to achieve the full diagnostic potential of the colorectal cancer biomarkers identified by our researchers," said Professor John Shine, Executive Director of Garvan. "Our hope is that the company will successfully develop a diagnostic tool that will be useful in the global effort to treat this common cancer."

About DNA Methylation

DNA methylation is a naturally occurring biological process involved in gene silencing. In 2005, a team led by Prof. Susan Clarke at the Garvan Institute of Medical Research published a paper in Nature Genetics describing a region of the human genome that shows much higher levels of methylation (silencing) in colorectal cancer compared to healthy controls.

About The Garvan Institute of Medical Research

The Garvan Institute of Medical Research is a world class institute focused on gene-based medical research with a strong focus on cancer and metabolic syndromes. World leading DNA methylation researcher Professor Susan Clark is the director of epigenetics research at the Garvan. Prof. Clark's track record includes pioneering the development of the bisulphite sequence protocol for detecting methylated cytosines now used around the world to measure gene silencing, discovery of the hyper-methylation of GSTP1 in prostate cancer and, more recently, contributions to understanding genome-wide methylation patterns in cancer.

About Clinical Genomics Pty Ltd

Clinical Genomics was formed in September 2006 to develop, extend, and commercialise molecular markers for colorectal disease. The enterprise includes experts in the science and business of colorectal cancer detection as well as institutional, commercial and clinical collaborative partners that understand this field. On top of a solid foundation of intellectual property protecting a panel of neoplasia biomarkers, CG has attracted significant financial and human resources to address this opportunity. By applying advanced biotechnology and computational technologies to study the complex changes in gene expression that occur as normal colorectal cells become cancerous, Clinical Genomics expect that an understanding of the molecular basis of the disease will enable them to provide products for improved diagnosis, management and possibly therapy of this disease.   Further Information:   Dr. Lindsay Collinson   Ph: +61 2 9888 9065 x 206   E: Lindsay.collinson@clinicalgenomics.com   Clinical Genomics Pty Ltd
'/>"/>

SOURCE Clinical Genomics Pty Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InspireMD Presents 2 Years Clinical Outcome of MGuard Multicenter Experience in STEMI Patients. The New Superb Clinical Results Were celebrated at InspireMDs TCT Satellite Symposium in Washington DC., Today.
2. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
3. China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic
4. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
5. Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus
6. 2010 Lasker Awards Honor Trailblazers in Medical Research and Clinical Care
7. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
8. Stemedica Announces Completion of Clinical Stem Cell Master Bank
9. Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. ChromaDex Commences a Clinical Trial on pTeroPureâ„¢ Pterostilbene
11. InSightec Treats First Prostate Cancer Patients in Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division ... tuned and optimized exclusively for Okuma CNC machining centers at The International Manufacturing ... collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics and ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):